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its first air quality evaluation tests in
Volgograd, using an American air quality
sampler that can measure inhalable partic-
ulates at the PM10 level, a standard signify-
ing particulate matter less than 10 millime-
ters in diameter. Until now, the Russians
were unable to measure particulates this
small. EPA researchers are currently ana-
lyzing the filters from those experiments to
determine the precise nature and sources of
the city's pollutants and to make further
recommendations.
"The Russian monitoring systems and
standards are currently configured much
differently than ours," says Jon Schweiss,
chief of the EPA air characterization sec-
tion based in Seattle and member ofthe air
quality evaluation team in Volgograd. "But
now they are considering suspending their
total particulate standard and replacing it
with one similar to our own. Throughout
this program, we've found the Russians to
be very open to new ideas-just tremen-
dously motivated and professional."
IARC on Risk
The International Agency for Research on
Cancer of the World Health Organization
held a five-day workshop in Lyon, France,
to discuss quantitative estimation and pre-
diction of carcinogenic risks (QEP). The
purpose of the workshop was to provide
IARC with some guidance concerning the
role they may play in providing research
support for QEP and on whether they
should expand their current risk assessment
activities to include QEP.
There has been increasing pressure on
[ARC in recent years to expand the mono-
graph program, which evaluates the
strength of the evidence for a carcinogenic
effect from an agent and generally does not
quantify the magnitude of that effect as a
function of the level of exposure to the
agent. In the standard paradigm for risk
assessment, QEP involves adding dose-
response evaluation and exposure assess-
ment to IARC's current hazard identifica-
tion role.
The workshop, held 18-22
October 1993, consisted of40
researchers and regulatory offi-
cials from North America,
Europe, Japan, and Australia.
The first three days of the
workshop focused on a review
of the methodology used for
QEP. The review consisted of
a general discussion of the
methods and the use of QEP
performed for three example
compounds: dioxin, radon,
and methylene chloride. Fol-
lowing the review, the work
group broke into four smaller
groups to draft background summaries on
QEP and to draft recommendations for
IARC.
The main recommendations of the
working group can be summarized as fol-
lows. First, the hazard indentification
process currently used by IARC for deter-
mining if an agent is carcinogenic should
be preserved in its present form. The work-
ing group felt that adding QEP to the cur-
rent IARC monograph program would
lead to a process that is unwieldly and dif-
ficult to manage. The working group also
said that the addition of QEP to the cur-
rent monograph series could detract from
its scientific excellence. However, the
group did say that IARC can and should
play a key role in risk estimation.
The second recommendation con-
cerned a variety of roles IARC could play
with regard to improving the scientific
validity of QEP. These include basic
research on QEP, a symposium on research
issues related to QEP, performance of
QEP for selected compounds, and the
publication of reports from these activities
in their IARC Monograph Series.
New Directions for IARC
The cornerstones ofepidemiology and lab-
oratory research will remain vital aspects of
the International Agency for Research on
Cancer, according to Paul Kleihues, who
assumed the IARC directorship in January.
While the agency intends to keep the bal-
ance between epidemiology research and
laboratory research, study will be expanded
in the area of cancer genetics, which
Kleihues called "traditionally underrepre-
sented," in a new unit to be created this
year.
According to Kleihues, the agency
plans to decrease its efforts in the areas of
mutagenesis and DNA adduct studies, pro-
grams [ARC has strongly developed in the
past, to allow for considerable expansion
into new aspects ofcancer research.
The first of these new areas will be a
4
I~~~~~I
Kleihues New director
seeks expansion of IARC.
new agency unit devoted to
studying the molecular aspects
of cancer, specifically genetic
susceptibility. Said Kleihues,
"We want to identify genes
which predispose people to
developing cancer, whether it
is spontaneous or induced by
exposure to environmental
carcinogens." For instance, he
added, "Many people smoke,
but only a small portion of
those develop lung cancer.
We want to know why 10 out
of 11 do not get cancer." The
new unit will also attempt to
identify in certain populations whether
there are genes that may protect people
from developing cancer.
Although considerable progress has
been made in the area ofchemoprevention
in the last three to four years, Kleihues
says, it is not enough. "Ifon the one hand
you can identify people at risk for cancer,
then on the other hand you must offer
these people some means to prevent it," he
said. For this reason, said Kleihues, IARC
will expand research into chemoprevention
ofcancer in a new unit that will investigate
prevention strategies for individuals who
are at high risk for developing cancer
because they are genetically predisposed,
have been exposed to high levels of envi-
ronmental carcinogens, or have developed
a single tumor in a site where multiple
tumors usually occur.
Kleihues outlined plans for the IARC
Monograph Series, which he called "one of
the more important and visible aspects of
the agency over the last 20 years." In a
move which he calls "a first and modest
step towards risk assessment," the series,
which in the past has been devoted to clas-
sifying carcinogenic agents based primarily
on animal and human data, will be
expanded to include data on mechanisms
of carcinogenesis. Understanding such
mechanisms, said Kleihues, is key to deter-
mining what agents will produce cancer in
humans. He stressed, however, that in the
foreseeable future, the agency "will not
engage in quantitative risk assessment."
Kleihues, who replaces Lorenzo
Tomatis as director ofIARC, obtained his
medical degree in 1962 from the
University of Munster in Westphalia,
Germany. From 1964 to 1976 he worked
as a research assistant at the Max-Planck
Institute for Brain Research in Cologne.
Kleihues served as a professor of neu-
ropathology and head of the Division of
Neuropathology in the Institute of
Pathology at the University ofFreiburg, in
Germany, from 1976 to 1983. In 1983 he
became a professor of neuropathology at
the University of Zurich and in 1992
assumed the directorship ofits newly creat-
ed Institute of Neuropathology before
leaving to take his position at IARC.
Kleihues called departing director
Tomatis the "father of the monograph
series" and says that the international
standing ofthe series is due in great part to
Tomatis's efforts. To his credit, Kleihues
said, Tomatis kept IARC an independent
institution, not subject to political or
national influences, which he called "a
remarkable achievement," and a goal he
plans to continue.
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